

Montserrat Torrebaddell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2407517/publications.pdf>

Version: 2024-02-01

28
papers

1,279
citations

933447

10
h-index

677142

22
g-index

29
all docs

29
docs citations

29
times ranked

2745
citing authors

#	ARTICLE	IF	CITATIONS
1	Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19 ⁺ positive acute lymphoblastic leukemia with isolated extramedullary disease. American Journal of Hematology, 2022, 97, 731-739.	4.1	6
2	Technical Validation and Clinical Utility of an NGS Targeted Panel to Improve Molecular Characterization of Pediatric Acute Leukemia. Frontiers in Molecular Biosciences, 2022, 9, 854098.	3.5	4
3	CD34 ⁺ CD19 ⁺ CD22 ⁺ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. Blood, 2022, 140, 38-44.	1.4	20
4	CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19 ⁺ Relapsed/Refractory Malignancies. Molecular Therapy, 2021, 29, 636-644.	8.2	80
5	An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report. Cancers, 2021, 13, 6148.	3.7	24
6	Factors associated with the clinical outcome of patients with relapsed/refractory CD19 ⁺ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. , 2021, 9, e003644.		11
7	Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia. Journal of Personalized Medicine, 2020, 10, 244.	2.5	1
8	Measurable Residual Disease Assessed by Flow-Cytometry Is a Stable Prognostic Factor for Pediatric T-Cell Acute Lymphoblastic Leukemia in Consecutive SEHOP Protocols Whereas the Impact of Oncogenetics Depends on Treatment. Frontiers in Pediatrics, 2020, 8, 614521.	1.9	3
9	Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Science Translational Medicine, 2019, 11, .	12.4	67
10	Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood, 2019, 133, 2291-2304.	1.4	87
11	A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2394-2404.	1.3	16
12	Paediatric patients with acute leukaemia and KMT2A (MLL) rearrangement show a distinctive expression pattern of histone deacetylases. British Journal of Haematology, 2018, 182, 542-553.	2.5	7
13	Spuriously low pulse oximetry saturation associated with hemoglobin Sydney in a child and relatives: Identification of this unstable hemoglobin may avoid unnecessary testing and hospital admissions. Pediatric Blood and Cancer, 2017, 64, e26317.	1.5	1
14	Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier. Journal of Controlled Release, 2017, 264, 34-44.	9.9	11
15	Aplastic Crisis Secondary to Parvovirus B19 Infection as the First Manifestation of an Undiagnosed Hereditary Spherocytosis. Journal of Pediatric Hematology/Oncology, 2016, 38, 81-82.	0.6	5
16	Microbial translocation and T cell activation are not associated in chronic HIV-infected children. Aids, 2014, 28, 1989-1992.	2.2	5
17	Prophylaxis of Invasive Pulmonary Aspergillosis with Nebulized Lipid Complex Amphotericin B Is Feasible, Well Tolerated and Safe in Children with Acute Leukemia. Results of a Phase II Open Trial. Blood, 2014, 124, 1409-1409.	1.4	0
18	Refining the Diagnosis and Prognostic Categorization of Acute Myeloid Leukemia Patients with an Integrated Use of Cytogenetic and Molecular Studies. Acta Haematologica, 2013, 129, 65-71.	1.4	3

#	ARTICLE	IF	CITATIONS
19	Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. <i>Blood</i> , 2013, 121, 2734-2738.	1.4	246
20	FLT3 Is Involved In Ara-C Transport By Human Equilibrative Nucleoside Transporter (hENT1) In Pediatric Acute Leukemia. <i>Blood</i> , 2013, 122, 3844-3844.	1.4	4
21	B cellâ€‘helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. <i>Nature Immunology</i> , 2012, 13, 170-180.	14.5	615
22	The Distinctive MicroRNA Signature of Acute Myeloid Leukemia with Translocation t(8;16)(p11;p13)/MYST3-CREBBP Is Responsible for RET Overexpression and Is Regulated by Epigenetic Mechanisms. <i>Blood</i> , 2011, 118, 2434-2434.	1.4	0
23	The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status. <i>Blood</i> , 2010, 116, 6147-6148.	1.4	41
24	A Distinctive MicroRNA Signature Characterizes Acute Myeloid Leukemia with Translocation (8;16)(p11;p13) and MYST3-CREBBP Rearrangement. <i>Blood</i> , 2010, 116, 230-230.	1.4	1
25	Assessment of CEBPA Mutations Might Contribute to a Better Prognostic Assignment in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009, 114, 2611-2611.	1.4	0
26	T-Cell Subpopulations Quantified by Flow Cytometry in Lymph Node Cell Suspensions Identify a Group of Patients with Follicular Lymphoma with Good Prognosis.. <i>Blood</i> , 2009, 114, 1945-1945.	1.4	0
27	Prognostic Value of Molecular Markers for Guiding Post-Remission Therapy in Patients with De Novo Acute Myeloid Leukemia (AML) and Intermediate-Risk Cytogenetics. <i>Blood</i> , 2008, 112, 2522-2522.	1.4	0
28	Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome. <i>Haematologica</i> , 2007, 92, 1655-1663.	3.5	21